Matthew Frigault
Overview
Explore the profile of Matthew Frigault including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
16
Citations
531
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Somasundaram E, Gill R, Hartford N, Collier K, McAfee S, Dey B, et al.
Transplant Cell Ther
. 2024 Nov;
31(1):45.e1-45.e7.
PMID: 39542361
Hematopoietic cell transplantation (HCT) remains the definitive therapeutic modality for numerous malignant and non-malignant hematologic disorders. Conventional bone marrow remains a viable donor source for HCT. However, microbial contamination of...
2.
Shadman M, Ahn K, Kaur M, Lekakis L, Beitinjaneh A, Iqbal M, et al.
Blood Cancer J
. 2024 Jul;
14(1):108.
PMID: 38977682
In patients with relapsed DLBCL in complete remission (CR), autologous hematopoietic cell transplantation (auto-HCT) and CAR-T therapy are both effective, but it is unknown which modality provides superior outcomes. We...
3.
Alsouqi A, Ahmed G, Wang J, Cassanello G, Szabo A, Rojek A, et al.
Am J Hematol
. 2024 May;
99(8):1624-1627.
PMID: 38769663
No abstract available.
4.
Wang T, Ahn K, Shadman M, Kaur M, Ahmed N, Bacher U, et al.
Leukemia
. 2024 May;
38(7):1564-1569.
PMID: 38750138
CD19 CAR T-cell (CAR-T) therapy is commonly administered to patients with relapsed or refractory large B-cell lymphomas (LBCL), but salvage or bridging therapy can sometimes lead to a complete response...
5.
Newcomb R, Gao L, Vanderklish J, Tse A, Saylor M, Danielson C, et al.
Transplant Cell Ther
. 2024 Apr;
30(7):700-711.
PMID: 38685402
Allogeneic hematopoietic cell transplantation (HCT) survivors may benefit from routine screening for post-transplant complications. However, the impact of formal survivorship efforts to promote screening adherence is uncertain. The effect of...
6.
Elsallab M, Ellithi M, Lunning M, DAngelo C, Ma J, Perales M, et al.
Blood
. 2024 Mar;
143(20):2099-2105.
PMID: 38483155
Second primary malignancies were reported in 536 of 12 394 (4.3%) adverse event reports following chimeric antigen receptor T-cell therapies in the Food and Drug Administration Adverse Event Reporting System....
7.
Little J, Tandon M, Hong J, Nadeem O, Sperling A, Raje N, et al.
Blood Adv
. 2023 Jul;
7(18):5485-5495.
PMID: 37486599
Infections are an important complication after B-cell maturation antigen (BCMA)-directed chimeric antigen receptor (CAR) T-cell therapy and risks may differ between the early and late periods. We evaluated infections in...
8.
Frigault M, Rotte A, Ansari A, Gliner B, Heery C, Shah B
J Exp Clin Cancer Res
. 2023 Jan;
42(1):11.
PMID: 36627710
CAR-T cells are widely recognized for their potential to successfully treat hematologic cancers and provide durable response. However, severe adverse events such as cytokine release syndrome (CRS) and neurotoxicity are...
9.
Jones D, Eckhardt C, Sun H, Tesh R, Malik P, Quadri S, et al.
Sci Rep
. 2022 Nov;
12(1):20011.
PMID: 36414694
CAR-T cell therapy is an effective cancer therapy for multiple refractory/relapsed hematologic malignancies but is associated with substantial toxicity, including Immune Effector Cell Associated Neurotoxicity Syndrome (ICANS). Improved detection and...
10.
Hanna P, Strohbehn I, Moreno D, Harden D, Seethapathy H, Gupta S, et al.
Bone Marrow Transplant
. 2022 Aug;
57(10):1623-1625.
PMID: 35922564
No abstract available.